BioWorld

Jan. 23, 2003

View Archived Issues

Millennium Files For Approval Of Velcade In Multiple Myeloma

Millennium Pharmaceuticals Inc. filed a new drug application for Velcade, a proteasome inhibitor shown to extend median survival time in relapsed and refractory multiple myeloma patients to 16.4 months. (BioWorld Today) Read More

Geron Reducing Staff Again To Push Lead Cancer Drug

Read More

From Bone Marrow Transplant To Brain Targets, Patient Autopsies See Stem Cells Creating Neurons

Read More

Amgen Files For Approval Of Enbrel In Ankylosing Spondylitis

Read More

Anthrax/Plague Vaccine Funds Will Help Avant With Pipeline

Read More

Other News To Note

Read More